Meet the one patient who will get access to this experimental ALS therapy before it’s approved

A biotechnology company had planned to make its experimental therapy for the deadly neuromuscular disease amyotrophic lateral sclerosis, or ALS, which has no cure, available to patients under a new “right to try” law championed by President Donald Trump.

But the problem, as so often is the case in the U.S. health care system, was price.

Brainstorm Cell Therapeutics Inc.’s BCLI, -1.52% stem cell-based treatment, which is personalized to the individual, would have an estimated price tag of more than $300,000 per patient, Chief Executive Chaim Lebovits told Bloomberg last week.

That’s comparable to cutting-edge cancer treatments used today, but Brainstorm’s therapy, NurOwn, has not been vetted by U.S.

>>> Original Source <<<